Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presently
become a rapidly spreading and devastating global pandemic. Veno-venous extracorporeal …

Despite increasing improvement in extracorporeal membrane oxygenation (ECMO)
technology and knowledge, thrombocytopenia and impaired platelet function are usual …

Anticoagulation of patients supported by extracorporeal membrane oxygenation is
challenging because of a high risk of both bleeding and thrombotic complications, and often …

Background Bleeding contributes to the high mortality of venovenous extracorporeal
membrane oxygenation (vvECMO). The development of acquired von Willebrand syndrome …

Background There is no consensus on the management of anticoagulation during
extracorporeal membrane oxygenation (ECMO). ECMO is currently burdened by a high rate …

Extracorporeal membrane oxygenation (ECMO) support has a high incidence of both
bleeding and thrombotic complications. Despite clear differences in patient characteristics …

Purpose The association between extracorporeal membrane oxygenation (ECMO) use and
the development of thrombocytopenia is widely presumed yet weakly demonstrated. We …

Background Thrombocytopenia has been proved to be associated with hospital mortality in
patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections …

Extracorporeal lung support and therapeutic anticoagulation are dogmatically linked for
most clinicians in fear of clotting of the extracorporeal circuit. In the last decade, however, we …

Since the last decade extracorporeal membrane oxygenation (ECMO) therapy has been
widely accepted as the treatment of life-threatening cardiac and pulmonary failure …